Mind Medicine Returns To Trough For Further $25.0 Million
Mind Medicine (NEO: MMED) continues to take investor dollars, this morning announcing a bought deal private placement for $25.0 million.
Read more
Mind Medicine
Mind Medicine: Canaccord Maintains Ratings Following Financial Results
On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results. Tania Gonsalves, Canaccord Genuity’s biotechnology
Read more
Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing
This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from C$1.75 to C$2.00 while reiterating
Read more
Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health
In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably been that of the growing
Read more
Mind Medicine To Conduct $25.0 Million Bought Deal Financing
Mind Medicine (CEO: MMED) announced that it will be conducting a bought deal financing this morning, to the tune of
Read more
Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event
This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from the recent two-day virtual non-deal
Read more
Mind Medicine Applies To List On The Nasdaq
Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist its stateside cross-listing to that
Read more
Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target
Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and a C$1.75 price target. Canaccord’s
Read more
MindMed Adds MDMA To R&D Pipeline
Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching out its research and development
Read more
Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price
Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as sole bookrunner. The financing, for
Read more